tradingkey.logo

Veracyte Q4 revenue rises 19%, beats expectations

ReutersFeb 25, 2026 9:14 PM


Overview

  • Cancer diagnostics firm's Q4 revenue rose 19%, beating analyst expectations

  • Testing revenue grew 21% driven by Decipher and Afirma tests

  • Company recorded GAAP net income of $41.1 mln, up 705% yr/yr


Outlook

  • Veracyte expects 2026 revenue growth of 10% to 13%, reaching $570 mln to $582 mln

  • Company projects 2026 testing revenue to grow 14% to 16%, reaching $560 mln to $570 mln

  • Veracyte anticipates 2026 adjusted EBITDA margin of approximately 25%


Result Drivers

  • DECIPHER AND AFIRMA GROWTH - Testing revenue increased 21% driven by Decipher and Afirma tests

  • CASH GENERATION - Generated $52.6 million of cash from operations in Q4


Company press release: ID:nBwb1stcfa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Beat

$140.60 mln

$133.62 mln (12 Analysts)

Q4 Net Income

$41.10 mln

Q4 Gross Margin

72.50%

Q4 Adjusted Operating Expenses

$65.10 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Veracyte Inc is $50.00, about 40.1% above its February 24 closing price of $35.69

  • The stock recently traded at 37 times the next 12-month earnings vs. a P/E of 49 three months ago


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI